Get the Stockscreener App
27.92
2.41%
-0.69
After Hours:
28.00
0.08
+0.29%
Maplight Therapeutics Inc stock is traded at $27.92, with a volume of 212.36K.
It is down -2.41% in the last 24 hours and up +31.88% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$28.61
Open:
$29
24h Volume:
212.36K
Relative Volume:
0.87
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-7.5157
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-7.89%
1M Performance:
+31.88%
6M Performance:
+74.50%
1Y Performance:
+0.00%
1-Day Range:
$27.76
$29.25
1-Week Range:
$26.39
$32.08
52-Week Range:
$12.24
$33.28
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
27.92 | 1.22B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Sahm
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by HC Wainwright - MarketBeat
HC Wainwright Initiates Coverage on MapLight Therapeutics With Buy Rating, $45 Price Target - Moomoo
Christopher Kroeger to sell MPLT shares (NASDAQ: MPLT) per Form 144 filing - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 5.5%Here's What Happened - MarketBeat
36,371 shares proposed sale via Jefferies for Maplight Therapeutics (NASDAQ: MPLT) - Stock Titan
Erin Foff sells 3,213 MPLT shares via Jefferies (MPLT) - Stock Titan
[144] MapLight Therapeutics, Inc. SEC Filing - Stock Titan
27,834-share proposed sale by Maplight Therapeutics (NASDAQ: MPLT) - Stock Titan
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April - Yahoo Finance
MapLight completes enrollment in two phase 2 CNS trials By Investing.com - Investing.com South Africa
MapLight completes enrollment in two phase 2 CNS trials - Investing.com
MapLight Therapeutics Completes Enrollment in ZEPHYR Phase 2 Trial for Schizophrenia and Final Patient Visit in IRIS Phase 2 Trial for Autism Spectrum Disorder - Quiver Quantitative
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results - The Manila Times
MapLight lines up schizophrenia and autism trial results by mid-August - Stock Titan
MPLT SEC FilingsMapLight Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
MapLight Therapeutics chief discovery officer sells $1.35 million in stock By Investing.com - Investing.com India
MapLight Therapeutics CAAO Jonathan Gillis sells $2.09 million stock By Investing.com - Investing.com India
MapLight Therapeutics CAAO Jonathan Gillis sells $2.09 million stock - Investing.com
Jonathan Gillis Sells 51,900 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock - MarketBeat
Anatol Kreitzer Sells 45,422 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 17,935 Shares of Stock - MarketBeat
Maplight Therapeutics Insider Sold Shares Worth $1,347,066, According to a Recent SEC Filing - marketscreener.com
MapLight Therapeutics Announces Board Refresh and New Nominees - TipRanks
69,835 MapLight (MPLT) shares sold under 10b5-1 trading plan - Stock Titan
MapLight Therapeutics (NASDAQ: MPLT) CDO sells 45,422 shares under 10b5-1 plan - Stock Titan
MapLight Therapeutics (MPLT) board shifts as two directors exit, two nominated - Stock Titan
[ARS] MapLight Therapeutics, Inc. SEC Filing - Stock Titan
MapLight Therapeutics (NASDAQ: MPLT) details 2026 director and auditor votes - Stock Titan
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
MPLT (NASDAQ) notice: 45,422 RSU shares proposed for resale - Stock Titan
Insider sale: 3,590 shares reported for MPLT (NASDAQ: MPLT) - Stock Titan
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
We're Hopeful That MapLight Therapeutics (NASDAQ:MPLT) Will Use Its Cash Wisely - Yahoo Finance
Maplight Therapeutics (NASDAQ:MPLT) Hits New 52-Week HighWhat's Next? - MarketBeat
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 12.8%Still a Buy? - MarketBeat
MapLight Therapeutics, Inc.Common Stock (Nasdaq:MPLT) Stock Quote - The Chronicle-Journal
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownHere's Why - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What macro factors move MapLight Therapeutics (MPLT) stock most (Trend Weakens) 2026-04-20Late Breakout - Cổng thông tin điện tử tỉnh Lào Cai
TD Cowen Initiates on MapLight (MPLT); Says It’s Undervalued on Schizophrenia Alone - Insider Monkey
MapLight Therapeutics (MPLT): The best healthcare stock insiders are buying - MSN
Maplight Therapeutics, Inc.'s (NASDAQ:MPLT) Lock-Up Period To Expire on April 27th - MarketBeat
5 Must-Buy Small Cap Stocks to Buy - Insider Monkey
MapLight Therapeutics CAAO sells $95k in MPLT stock By Investing.com - Investing.com India
MapLight Therapeutics Leadership Quietly Unloads a Wave of Shares - TipRanks
MapLight Therapeutics CFO Setia Vishwas sells $78,572 in shares - Investing.com
MapLight Therapeutics CFO Setia Vishwas sells $78,572 in shares By Investing.com - Investing.com India
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):